prof. Vibeke Kruse
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - VIBEKE.KRUSE@UGent.be
Show
Sort by
-
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma
-
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
-
- Journal Article
- A1
- open access
Throughput efficiency and service quality after process redesign at a cancer day care unit: Two sides of the coin?
-
- Journal Article
- A1
- open access
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
-
- Journal Article
- A2
- open access
Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor : case report and literature review
-
Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis
-
Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma
-
- Journal Article
- A2
- open access
Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
-
The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital
-
Cost-effectiveness and budget effect analysis of a population-based skin cancer screening